市场调查报告书
商品编码
1154861
全球细胞健康诊断市场规模、份额、行业趋势分析报告:2022-2028 年各样本类型、采样点、测试类型、地区的展望和预测Global Cellular Health Screening Market Size, Share & Industry Trends Analysis Report By Sample Type, By Collection Site, By Test Type, By Regional Outlook and Forecast, 2022 - 2028 |
到 2028 年,全球细胞健康筛查市场规模预计将达到 43 亿美元,预测期内復合年增长率为 9.0%。
精准医学的一个关键组成部分是通过细胞健康筛查轻鬆监测和控制治疗方案。此外,它越来越多地用于常规体检,因为它提供有关细胞活动和肌肉质量的信息。
如果您没有任何症状,将进行筛查测试以检查是否存在可能的健康问题或疾病。目标是及早发现、改变生活方式或进行监测,以降低患病的可能性或获得最佳治疗。
COVID-19 影响分析
由于 COVID-19 大流行,提供移动健康筛查产品和服务的公司的收入和基本检测量有所下降。除了与大流行病相关的政府命令外,运输限制以及对货物和原材料进出口的禁令也扰乱了供应链。因此,许多公司扩大了他们的产品范围,将 COVID-19 抗体和分子测试纳入其中,以平衡减少的基线测试能力,以应对供应链中断导致的需求减少。我能够接受。
市场增长因素
世界上老龄化人口的增长
由于衰老和不平衡的生活方式是人体膳食失衡的主要原因,因此细胞健康检查必不可少。市场上也有补充剂可以提高营养水平。氧化应激、疲劳、压力以及其他症状的根本原因是细胞健康状况不佳。然而,缺乏必需的营养素会逐渐限制细胞的正常活动并导致疾病。 NAD+ 的水平是所有细胞发挥最佳功能所必需的一种□,据说在 40 到 60 岁之间会减少一半。此外,缩短的端粒会导致多种副作用,包括肝病、肺纤维化和骨髓衰竭。
扩大个性化药物的使用
细胞健康筛查之所以流行,是因为它在个性化医疗中的应用越来越广泛。国际个性化医疗联盟 (ICPerMed) 认为,技术创新是推动 PM 以及生物医学、社会和经济科学进步的动力。因此,其成功需要对创新和研究进行大量投资。个性化医疗通常由两部分组成。生物製剂、药物疗法和其他治疗干预是第一部分,诊断测试是第二部分。
市场製约因素
细胞筛选试剂盒成本高,缺乏专家
由于便携式健康检查套件的成本高昂,大多数人无力使用它们。影响细胞健康筛查生长的另一个方面是样本脆弱性和试剂盒不稳定性。两者都会降低程序响应能力和流程效率。它的高维护性使其不适合在所有情况下使用,尤其是在采样受限的情况下。此外,越来越多的样品运输挑战和不利的退款政策降低了对便携式健康检查套件的偏好。
样本类型展望
按样本类型,细胞健康筛查市场分为血液、唾液、血清和尿液。 2021 年,尿液样本部分在细胞健康筛查市场中占据了很大的收入份额。尿液收集不需要技术人员,而且是非侵入性的,因此对患者友好且速度非常快。此外,研究表明尿液筛查可以准确评估氧化应激。例如,日本研究人员在一篇研究论文中证明,吸烟和氧化应激与尿液中蝶啶化合物的含量有关。因此,体内氧化应激的筛查将会推进,基于尿液样本的筛查市场有望上升。
采集点前景
细胞健康筛查市场按采集地点细分为家庭、办公室、医院和诊断实验室。 2021 年,家庭部门在细胞健康筛查市场中获得了可观的收入份额。这可以通过重要市场中日益增长的健康意识和自我采样的流行来解释。自我采样因其易于使用且不需要专门设备或合格人员而广受欢迎。由于行动受到限制,COVID-19 大流行还导致了一种普遍的家庭收集趋势,而且这种趋势可能会持续下去。
按测试类型划分的前景
细胞健康筛查市场按检测类型分为单检测组和多检测组。 2021 年,单一检测试剂盒以最高收入份额主导细胞健康筛查市场。用于单板检测的产品可为特定类别的疾病提供经济实惠、准确且快速的筛查。一个简单的单面板测试使用样本来检测可能是疾病前兆的生物标誌物。此类诊断测试可以在企业和个人环境中进行,例如在工作场所或家中。几分钟之内,您就会获得可见且易于理解的定性数据。
氧化应激测试的前景
单试板划分又分为端粒测试、氧化应激测试、炎症测试、重金属测试。氧化应激测试将在 2021 年占据细胞□□健康筛查市场的最大收入份额。这些测试有助于癌症、呼吸系统疾病、糖尿病、心血管疾病和其他疾病。氧化应激是自由基(ROS,活性氧)的产生与体内已有的抗氧化能力 (AC) 之间失衡的结果。当抗氧化力增加时,活性氧的产生受到抑制,反之,当抗氧化力增加时,活性氧的值通常会降低。
区域展望
按地区划分,分析了北美、欧洲、亚太地区和 LAMEA 的细胞健康筛查市场。 2021 年,北美地区在细胞健康筛查市场的收入份额最大。该地区的主要贡献者包括健康预期寿命 (HALE)、不断上升的医疗保健成本以及政府对预防性医疗保健的支持。此外,重要公司的存在、新技术的易于采用、慢性病和传染病在人口中的流行等都有助于该地区的增长。
细胞健康筛查市场的报导。
报告属性详细信息
2021 年市场规模 24 亿美元
2028 年市场规模预测 43 亿美元
基准年 2021
2018-2020 年
预测期 2022-2028
从 2022 年到 2028 年,收入复合年增长率为 9%。
250页
表460
报告涵盖的市场趋势、盈利预测和预测、细分市场分析、地区/国家细分、公司战略发展、公司概况
目标细分样本类型、采样点、测试类型、地区
美国、加拿大、墨西哥、德国、英国、法国、俄罗斯、西班牙、意大利、中国、日本、印度、韩国、新加坡、澳大利亚、巴西、阿根廷、阿联酋、沙特阿拉伯、南非、尼日利亚
驱动因素:全球老龄化人口不断增长
扩大个性化药物的使用
制约因素:细胞筛选试剂盒成本高,缺乏专业人员
The Global Cellular Health Screening Market size is expected to reach $4.3 billion by 2028, rising at a market growth of 9.0% CAGR during the forecast period.
Cellular health screening is a cutting-edge innovation used to quickly assess cellular health. The screening illustrates how the cells function in relation to the body. The screening aids in determining conditions such as cellular toxicity, fat mass, cellular capabilities, dynamic tissue mass, and extracellular and intracellular liquid levels. The fundamental components of life are cells, which come together to form organs.
Bio-energy is produced by healthy cells, which eventually results in normal health. Since it can accurately assess a person's level of health and provide details about cellular health and performance, cellular health screening has grown in importance in recent years. This screening method helps doctors and other healthcare professionals better understand how cells in the body behave and function.
A key component of precision medicine is the easy monitoring and control of treatment options made possible by cellular health screening. Additionally, it provides information on cellular activity and muscle mass, which has increased its adoption in routine health examinations.
When a person does not exhibit any symptoms of a condition, a screening test is performed to look for probable health issues or diseases. The objective is early identification, lifestyle modifications, or surveillance to lower the likelihood of disease or to identify it soon enough to receive the best possible care.
Covid-19 Impact Analysis
As a consequence of the COVID-19 pandemic, businesses that provide cellular health screening products and services saw a decline in their revenues and base testing volume. Along with the government directives connected to the pandemic, the supply chain was hampered by transportation constraints and prohibitions on the export and import of commodities and raw materials. Consequently, many companies expanded their product offerings to incorporate COVID-19 antibody and molecular testing in response to the fall in demand brought on by the interruption of the supply chain, which could balance the decrease in a base testing capacity.
Market Growth Factors
Rise in the global geriatric population
Cellular health screening is essential because aging and poor lifestyles are the main sources of dietary imbalances in the human body. Commercially available supplements are available to boost nutritional levels. The fundamental cause of oxidative stress, fatigue, stress, as well as other symptoms is a decline in cell health. However, a lack of necessary nutrients will gradually limit cells' ability to operate normally, which will lead to sickness. The levels of NAD+, an enzyme needed by every cell for optimal operation, decrease by half between the ages of 40 and 60. Additionally, a shorter telomere can result in a number of side effects, including liver illness, lung fibrosis, and bone marrow failure.
Expanded Use of Personalized Medicines
The growth of cellular health screening is attributed to its expanding use in personalized medicine. The International Consortium for Personalized Medicine (ICPerMed) considers that technology innovation, along with the advancement of the biomedical, social, and economic sciences, is what propels PM. Therefore, a significant investment in innovation and research is necessary for its successful execution. Personalized medicine generally consists of two components. A biological, medication or any other form of therapeutic intervention is the first, and a diagnostic test is the second.
Market Restraining Factors
High cost of cellular screening kits and lack of specialized workers
The cost of cellular health screening kits can be high, which sustains their usage by the majority beyond a point. Another aspect that has an impact on the growth of Cellular Health Screening is the fragility of samples and the instability of kits. Both of these reduce the responsiveness of the program and the efficiency of the process. Their high maintenance has made them ineligible to be used in every case, especially in cases where the sample collection is limited. Additionally, the rising sample transportation challenges and unfavorable reimbursement policies decline the preference for cellular health screening kits.
Sample Type Outlook
On the basis of sample type, the cellular health screening market is divided into blood, saliva, serum, and urine. The urine sample segment witnessed a significant revenue share in the cellular health screening market in 2021. Since urine collection does not require technical people and is non-invasive, it is patient-friendly and significantly quicker. Additionally, studies have shown that urine screening may accurately assess oxidative stress. For instance, researchers from Japan demonstrated in a study article that smoking and oxidative stress are linked to the level of pteridine compounds in urine. As a result, the market for urine sample type screening is predicted to rise as a result of the growing screening of oxidative stress in the body.
Collection Site Outlook
Based on collection site, the cellular health screening market is segmented into home, office, hospital, and diagnostic labs. The home segment procured a promising revenue share in the cellular health screening market in 2021. This is explained by rising health consciousness and the widespread use of self-sampling in important marketplaces. Self-sampling has become popular because it is simple to use and doesn't call for specialized equipment or qualified personnel. Additionally, the COVID-19 pandemic resulted in a widespread inclination for home collections because of the restrictions on movement, and this inclination will persist for years to come.
Test Type Outlook
Based on test type, the cellular health screening market is categorized into single test panels and multi-test panels. The single test panels dominated the cellular health screening market with the highest revenue share in 2021. Products for single-panel tests offer affordable, precise, and quick screening for a specific, particular class of disease. Simple single panel tests use a sample to detect biomarkers that could be precursors for the disease. Such diagnostic tests are appropriate for both business and personal use, whether conducted in the workplace or at home. Within minutes, tests produce qualitative data that are visible and easy to comprehend.
Oxidative Stress Tests Outlook
The single test panels segment is further divided into telomere tests, oxidative stress tests, inflammation tests, and heavy metals tests. The oxidative stress tests acquired the largest revenue share in the cellular health screening market in 2021. Cancer, respiratory conditions, diabetes, cardiovascular conditions, and other illnesses are helped by these tests. Oxidative stress is a result of an imbalance between the generation of free radicals (ROS, or reactive oxygen species), and the body's already-existing antioxidant capacity (AC). An enhancement in antioxidant capacity frequently results in a decrease in ROS generation, whilst a rise in the AC may result in a drop in ROS values.
Regional Outlook
On the basis of region, the cellular health screening market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North American region recorded the largest revenue share in the cellular health screening market in 2021. Healthy Life Expectancy (HALE), which measures how long people live in good health, rising healthcare costs, and government support for preventative care are some of the major contributing elements in this area. Additionally, the existence of significant important players, the simplicity with which new technologies are adopted, and the prevalence of chronic and infectious diseases among the populace all contribute to regional growth.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Quest Diagnostics Incorporated, OPKO Health, Inc., Laboratory Corporation of America Holdings, Genova Diagnostics, Telomere Diagnostics, Inc., Life Length, S.L., Repeat Diagnostics, Inc., SpectraCell Laboratories, Inc. (Beingmate Group Co. Ltd.), Cell Science Systems Corp. and Segterra, Inc.
Cellular Health Screening Market Report Coverage:
Report Attribute Details
Market size value in 2021 USD 2.4 Billion
Market size forecast in 2028 USD 4.3 Billion
Base Year 2021
Historical period 2018 to 2020
Forecast Period 2022 to 2028
Revenue Growth Rate CAGR of 9% from 2022 to 2028
Number of Pages 250
Tables 460
Report coverage Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Companies Strategic Developments, Company Profiling
Segments covered Sample Type, Collection Site, Test Type, Region
Country scope US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Singapore, Australia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria
Growth Drivers * Rise in the global geriatric population
Expanded Use of Personalized Medicines
Restraints * High cost of cellular screening kits and lack of specialized workers
Market Segments covered in the Report:
By Sample Type
By Collection Site
By Test Type
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures